{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:53:36Z","timestamp":1771566816582,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018529","name":"Alkermes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03211-w","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:06:24Z","timestamp":1748995584000},"page":"3691-3707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Healthcare Resource Utilization 6\u00a0Months Before and After Olanzapine\/Samidorphan Initiation: Real-World Assessment of Patients with Schizophrenia or Bipolar\u00a0I Disorder"],"prefix":"10.1007","volume":"42","author":[{"given":"Andrew J.","family":"Cutler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4501-9484","authenticated-orcid":false,"given":"Hemangi R.","family":"Panchmatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro G.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah S.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Doane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"3211_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/CEOR.S259338","volume":"12","author":"L Bessonova","year":"2020","unstructured":"Bessonova L, Ogden K, Doane MJ, O\u2019Sullivan AK, Tohen M. The economic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:481\u201397.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3211_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12991-023-00440-7","volume":"22","author":"C Dembek","year":"2023","unstructured":"Dembek C, Mackie D, Modi K, Zhu Y, Niu X, Grinnell T. The economic and humanistic burden of bipolar disorder in adults in the United States. Ann Gen Psychiatry. 2023;22:13.","journal-title":"Ann Gen Psychiatry"},{"key":"3211_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2017.09.011","volume":"226","author":"M Cloutier","year":"2018","unstructured":"Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar\u00a0I disorder in the United States in 2015. J Affect Disord. 2018;226:45\u201351.","journal-title":"J Affect Disord"},{"key":"3211_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4088\/JCP.15m10278","volume":"77","author":"M Cloutier","year":"2016","unstructured":"Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77:764\u201371.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR5","doi-asserted-by":"publisher","first-page":"22m14458","DOI":"10.4088\/JCP.22m14458","volume":"83","author":"A Kadakia","year":"2022","unstructured":"Kadakia A, Catillon M, Fan Q, et al. The economic burden of schizophrenia in the United States. J Clin Psychiatry. 2022;83:22m14458.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR6","volume":"15","author":"A Girdhar","year":"2023","unstructured":"Girdhar A, Patil R. Caregivers\u2019 burden in patients with bipolar disorder and schizophrenia and its relationship with anxiety and depression in caregivers: a narrative review. Cureus. 2023;15:e47497.","journal-title":"Cureus"},{"key":"3211_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12888-022-04069-w","volume":"22","author":"GJ Karambelas","year":"2022","unstructured":"Karambelas GJ, Filia K, Byrne LK, Allott KA, Jayasinghe A, Cotton SM. A systematic review comparing caregiver burden and psychological functioning in caregivers of individuals with schizophrenia spectrum disorders and bipolar disorders. BMC Psychiatry. 2022;22:422.","journal-title":"BMC Psychiatry"},{"key":"3211_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4103\/ipj.ipj_28_21","volume":"30","author":"KJ Tanna","year":"2021","unstructured":"Tanna KJ. Evaluation of burden felt by caregivers of patients with schizophrenia and bipolar disorder. Ind Psychiatry J. 2021;30:299\u2013304.","journal-title":"Ind Psychiatry J"},{"key":"3211_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/nop2.1205","volume":"9","author":"F Rahmani","year":"2022","unstructured":"Rahmani F, Roshangar F, Gholizadeh L, Asghari E. Caregiver burden and the associated factors in the family caregivers of patients with schizophrenia. Nurs Open. 2022;9:1995\u20132002.","journal-title":"Nurs Open"},{"key":"3211_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12888-022-04289-0","volume":"22","author":"WL Cheng","year":"2022","unstructured":"Cheng WL, Chang CC, Griffiths MD, et al. Quality of life and care burden among family caregivers of people with severe mental illness: mediating effects of self-esteem and psychological distress. BMC Psychiatry. 2022;22:672.","journal-title":"BMC Psychiatry"},{"key":"3211_CR11","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/NDT.S139075","volume":"13","author":"G Ayano","year":"2017","unstructured":"Ayano G, Duko B. Relapse and hospitalization in patients with schizophrenia and bipolar disorder at the St Amanuel mental specialized hospital, Addis Ababa, Ethiopia: a comparative quantitative cross-sectional study. Neuropsychiatr Dis Treat. 2017;13:1527\u201331.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3211_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112559","volume":"281","author":"ML Bozzay","year":"2019","unstructured":"Bozzay ML, Gaudiano BA, Arias S, Epstein-Lubow G, Miller IW, Weinstock LM. Predictors of 30-day rehospitalization in a sample of hospitalized patients with bipolar\u00a0I disorder. Psychiatry Res. 2019;281:112559.","journal-title":"Psychiatry Res"},{"key":"3211_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4088\/JCP.v69n0107","volume":"69","author":"MR Law","year":"2008","unstructured":"Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69:47\u201353.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1176\/appi.ps.201800511","volume":"70","author":"DG Robinson","year":"2019","unstructured":"Robinson DG, Schooler NR, Rosenheck RA, et al. Predictors of hospitalization of individuals with first-episode psychosis: data from a 2-year follow-up of the RAISE-ETP. Psychiatr Serv. 2019;70:569\u201377.","journal-title":"Psychiatr Serv"},{"key":"3211_CR15","doi-asserted-by":"publisher","first-page":"1140908","DOI":"10.3389\/fpsyt.2023.1140908","volume":"14","author":"X Shi","year":"2023","unstructured":"Shi X, Zhao Y, Yang H, et al. Factors associated with hospitalization times and length of stay in patients with bipolar disorder. Front Psychiatry. 2023;14:1140908.","journal-title":"Front Psychiatry"},{"key":"3211_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15386\/mpr-2144","volume":"95","author":"A Velelekou","year":"2022","unstructured":"Velelekou A, Papathanasiou IV, Alikari V, Papagiannis D, Tsaras K, Fradelos EC. Factors influencing the duration of hospitalization of patients with schizophrenia. Med Pharm Rep. 2022;95:290\u20139.","journal-title":"Med Pharm Rep"},{"key":"3211_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2217\/cer-2018-0090","volume":"8","author":"T Yan","year":"2019","unstructured":"Yan T, Greene M, Chang E, et al. Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar\u00a0I disorder or major depressive disorder. J Comp Eff Res. 2019;8:217\u201327.","journal-title":"J Comp Eff Res"},{"key":"3211_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ps.201000505","volume":"63","author":"WB Hawthorne","year":"2012","unstructured":"Hawthorne WB, Folsom DP, Sommerfeld DH, et al. Incarceration among adults who are in the public mental health system: rates, risk factors, and short-term outcomes. Psychiatr Serv. 2012;63:26\u201332.","journal-title":"Psychiatr Serv"},{"key":"3211_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/jphs.12004","volume":"4","author":"J Panish","year":"2013","unstructured":"Panish J, Karve S, Candrilli SD, Dirani R. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US medicaid-enrolled patients with schizophrenia. J Pharm Health Serv Res. 2013;4:29\u201339.","journal-title":"J Pharm Health Serv Res"},{"key":"3211_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12888-023-04558-6","volume":"23","author":"AJ Perkins","year":"2023","unstructured":"Perkins AJ, Khandker R, Overley A, et al. The impact of antipsychotic adherence on acute care utilization. BMC Psychiatry. 2023;23:64.","journal-title":"BMC Psychiatry"},{"key":"3211_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/13696998.2018.1543188","volume":"22","author":"MS Broder","year":"2019","unstructured":"Broder MS, Greene M, Chang E, Hartry A, Yan T, Yermilov I. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar\u00a0I disorder. J Med Econ. 2019;22:63\u201370.","journal-title":"J Med Econ"},{"key":"3211_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21:127\u201334.","journal-title":"J Med Econ"},{"key":"3211_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12888-020-02767-x","volume":"20","author":"L Bessonova","year":"2020","unstructured":"Bessonova L, Velligan DI, Weiden PJ, et al. Antipsychotic treatment experiences of people with bipolar\u00a0I disorder: patient perspectives from an online survey. BMC Psychiatry. 2020;20:354.","journal-title":"BMC Psychiatry"},{"key":"3211_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","volume":"18","author":"E Achtyes","year":"2018","unstructured":"Achtyes E, Simmons A, Skabeev A, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018;18:292.","journal-title":"BMC Psychiatry"},{"key":"3211_CR25","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/PPA.S270020","volume":"14","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Sajatovic M, Weiden PJ, et al. Antipsychotic treatment experiences of people with schizophrenia: patient perspectives from an online survey. Patient Prefer Adherence. 2020;14:2043\u201354.","journal-title":"Patient Prefer Adherence"},{"key":"3211_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"3211_CR27","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"key":"3211_CR28","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","volume":"378","author":"A Cipriani","year":"2011","unstructured":"Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306\u201315.","journal-title":"Lancet"},{"key":"3211_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"3211_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","volume":"61","author":"N Bhana","year":"2001","unstructured":"Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111\u201361.","journal-title":"Drugs"},{"key":"3211_CR31","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","volume":"162","author":"A Breier","year":"2005","unstructured":"Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879\u201387.","journal-title":"Am J Psychiatry"},{"key":"3211_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1524-4733.2008.00495.x","volume":"12","author":"J Alonso","year":"2009","unstructured":"Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the schizophrenia health outcomes (SOHO) study. Value Health. 2009;12:536\u201343.","journal-title":"Value Health"},{"key":"3211_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/archpsyc.60.12.1218","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218\u201326.","journal-title":"Arch Gen Psychiatry"},{"key":"3211_CR34","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1176\/ps.48.12.1571","volume":"48","author":"MA Dellva","year":"1997","unstructured":"Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv. 1997;48:1571\u20137.","journal-title":"Psychiatr Serv"},{"key":"3211_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1478-7547-7-4","volume":"7","author":"NM Furiak","year":"2009","unstructured":"Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7:4.","journal-title":"Cost Eff Resour Alloc"},{"key":"3211_CR36","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","volume":"27","author":"T Kishi","year":"2022","unstructured":"Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2022;27:1136\u201344.","journal-title":"Mol Psychiatry"},{"key":"3211_CR37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686\u201396.","journal-title":"Am J Psychiatry"},{"key":"3211_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4088\/JCP.v60n0602","volume":"60","author":"DA Wirshing","year":"1999","unstructured":"Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358\u201363.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","volume":"101","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase\u00a01. Schizophr Res. 2008;101:273\u201386.","journal-title":"Schizophr Res"},{"key":"3211_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4088\/JCP.10m06497","volume":"73","author":"RL Berkowitz","year":"2012","unstructured":"Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the clinical antipsychotic trials of intervention effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry. 2012;73:498\u2013503.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR41","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1185\/030079906X148616","volume":"22","author":"TA Ketter","year":"2006","unstructured":"Ketter TA, Haupt DW. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin. 2006;22:2345\u201353.","journal-title":"Curr Med Res Opin"},{"key":"3211_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ijnp\/pyad029","volume":"26","author":"CU Correll","year":"2023","unstructured":"Correll CU, H\u00f8jlund M, Graham C, Todtenkopf MS, McDonnell D, Simmons A. Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis. Int J Neuropsychopharmacol. 2023;26:451\u201364.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3211_CR43","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231\u201341.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3211_CR44","unstructured":"Lybalvi [package insert]. Waltham, MA: Alkermes, Inc.; 2024."},{"key":"3211_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","volume":"176","author":"WF Martin","year":"2019","unstructured":"Martin WF, Correll CU, Weiden PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase\u00a02 study in patients with schizophrenia. Am J Psychiatry. 2019;176:457\u201367.","journal-title":"Am J Psychiatry"},{"key":"3211_CR46","doi-asserted-by":"publisher","first-page":"19m12769","DOI":"10.4088\/JCP.19m12769","volume":"81","author":"SG Potkin","year":"2020","unstructured":"Potkin SG, Kunovac J, Silverman BL, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase\u00a03 ENLIGHTEN-1 study. J Clin Psychiatry. 2020;81:19m12769.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR47","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","volume":"177","author":"CU Correll","year":"2020","unstructured":"Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase\u00a03 study. Am J Psychiatry. 2020;177:1168\u201378.","journal-title":"Am J Psychiatry"},{"key":"3211_CR48","doi-asserted-by":"publisher","first-page":"22m14674","DOI":"10.4088\/JCP.22m14674","volume":"84","author":"RS Kahn","year":"2023","unstructured":"Kahn RS, Kane JM, Correll CU, et al. Olanzapine\/samidorphan in young adults with schizophrenia, schizophreniform disorder, or bipolar\u00a0I disorder who are early in their illness: results of the randomized, controlled ENLIGHTEN-Early study. J Clin Psychiatry. 2023;84:22m14674.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1017\/S1092852920001376","volume":"26","author":"S Yagoda","year":"2020","unstructured":"Yagoda S, Graham C, Simmons A, Arevalo C, Jiang Y, McDonnell D. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectr. 2020;26:383\u201392.","journal-title":"CNS Spectr"},{"key":"3211_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.schres.2021.04.009","volume":"232","author":"RS Kahn","year":"2021","unstructured":"Kahn RS, Silverman BL, DiPetrillo L, et al. A phase\u00a03, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. Schizophr Res. 2021;232:45\u201353.","journal-title":"Schizophr Res"},{"key":"3211_CR51","doi-asserted-by":"publisher","first-page":"24m15511","DOI":"10.4088\/JCP.24m15511","volume":"86","author":"JS Ballon","year":"2024","unstructured":"Ballon JS, Kahn RS, Arevalo C, Dunbar M, McDonnell D, Correll CU. Long-term safety, tolerability, and durability of treatment effect of olanzapine and samidorphan: results of a 4-year open-label study. J Clin Psychiatry. 2024;86:24m15511.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 4","key":"3211_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","volume":"70","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1\u201346.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR53","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","volume":"55","author":"PJ Weiden","year":"2004","unstructured":"Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886\u201391.","journal-title":"Psychiatr Serv"},{"key":"3211_CR54","unstructured":"US Department of Health and Human Services. \u00a746.104 Exempt research. Code of Federal Regulations. https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-A\/part-46\/subpart-A\/section-46.104#p-46.104(d)(7). Accessed 1 Aug 2023."},{"key":"3211_CR55","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","journal-title":"Am J Epidemiol"},{"key":"3211_CR56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M De Hert","year":"2012","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114\u201326.","journal-title":"Nat Rev Endocrinol"},{"key":"3211_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64\u201377.","journal-title":"Lancet Psychiatry"},{"issue":"Suppl 21","key":"3211_CR58","first-page":"5","volume":"60","author":"I Kawachi","year":"1999","unstructured":"Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry. 1999;60(Suppl 21):5\u20139.","journal-title":"J Clin Psychiatry"},{"key":"3211_CR59","first-page":"204800401663337","volume":"5","author":"TS Han","year":"2016","unstructured":"Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016;5:2048004016633371.","journal-title":"JRSM Cardiovasc Dis"},{"key":"3211_CR60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2165\/11589060-000000000-00000","volume":"31","author":"L Citrome","year":"2011","unstructured":"Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31:455\u201382.","journal-title":"Clin Drug Investig"},{"key":"3211_CR61","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.2147\/NDT.S313840","volume":"17","author":"L Citrome","year":"2021","unstructured":"Citrome L, Graham C, Simmons A, et al. An evidence-based review of OLZ\/SAM for treatment of adults with schizophrenia or bipolar\u00a0I disorder. Neuropsychiatr Dis Treat. 2021;17:2885\u2013904.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3211_CR62","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MLR.0b013e318040ad90","volume":"45","author":"FR Johnson","year":"2007","unstructured":"Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care. 2007;45:545\u201352.","journal-title":"Med Care"},{"key":"3211_CR63","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/13696998.2021.1890428","volume":"24","author":"H Huang","year":"2021","unstructured":"Huang H, Schmerold L, Dembek C, et al. Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine. J Med Econ. 2021;24:352\u201362.","journal-title":"J Med Econ"},{"key":"3211_CR64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10488-023-01327-1","volume":"51","author":"K Richards","year":"2023","unstructured":"Richards K, Johnsrud M, Zacker C, Sasan\u00e9 R. One-year medication treatment patterns, healthcare resource utilization, and expenditures for medicaid patients with schizophrenia starting oral atypical antipsychotic medication. Adm Policy Ment Health. 2023;51:207\u201316.","journal-title":"Adm Policy Ment Health"},{"key":"3211_CR65","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2147\/CEOR.S402357","volume":"15","author":"D Hadzi Boskovic","year":"2023","unstructured":"Hadzi Boskovic D, Liang S, Parab P, Wiggins E, Liberman JN. Real-world evidence of aripiprazole tablets with sensor: treatment patterns and impacts on psychiatric healthcare resource utilization. Clinicoecon Outcomes Res. 2023;15:487\u201398.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3211_CR66","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/13696998.2019.1685818","volume":"23","author":"R Ayyagari","year":"2020","unstructured":"Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders. J Med Econ. 2020;23:204\u201312.","journal-title":"J Med Econ"},{"key":"3211_CR67","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12325-013-0016-5","volume":"30","author":"S Offord","year":"2013","unstructured":"Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30:286\u201397.","journal-title":"Adv Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03211-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03211-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03211-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:53:47Z","timestamp":1757184827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03211-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3211"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03211-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew J. Cutler has acted as consultant for 4M Therapeutics, AbbVie, Acadia, Alfasigma, Alkermes, Anavex Life Sciences, Autobahn Therapeutics, Axsome, Biogen, Biohaven, Boehringer Ingelheim, Brii Biosciences, Bristol Myers Squibb, Cerevel, Corium, Delpor, Evolution Research Group, Intra-Cellular Therapies, J&J Innovative Medicine, Jazz Pharma, Karuna, LivaNova, Lundbeck, Luye Pharma, MapLight Therapeutics, MedAvante-ProPhase, Mentavi, Neumora, Neurocrine, Neuroscience Education Institute, NeuroSigma, Noven, Otsuka, PaxMedica, Relmada, Sage Therapeutics, Supernus, Teva, Thynk, Tris Pharma, Vanda Pharmaceuticals, and VistaGen Therapeutics; has received speaker\/promotional honoraria from AbbVie, Alfasigma, Alkermes, Axsome, Bristol Myers Squibb, Corium, Intra-Cellular Therapies, J&J, Lundbeck, Neurocrine, Noven, Otsuka, Supernus, Teva, Tris Pharma, and Vanda Pharmaceuticals; holds stock options in 4M Therapeutics; and has served on a data safety monitoring board for Alar Pharma, COMPASS Pathways, Freedom Biosciences, and Pain Therapeutics. Hemangi R. Panchmatia and Michael J. Doane are or were employees of Alkermes, Inc., and may own stock\/options in the company. Alejandro G. Hughes and Noah S. Webb are employees of Optum, Inc., a health services innovation company that received funding from Alkermes, Inc., to conduct this study and analyze the data used for this publication. Rakesh Jain has acted as consultant for AbbVie, Acadia, Adamas, Alfasigma, Alkermes, Almatica, Axsome, Biogen, Boehringer Ingelheim, Cingulate Therapeutics, Corium, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva, Transcend Therapeutics, and Viatris; has received speaker\/promotional honoraria from AbbVie, Alkermes, Almatica, Axsome, Corium, Eisai, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Tris Pharmaceuticals, and Viatris; has served on an advisory board for Adamas, Alkermes, Corium, Eisai, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, and Teva; and has received research funding from AbbVie, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this study used only deidentified patient records and did not involve the collection, use, or transmittal of individually identifiable data, it was exempted from institutional review board review [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}